Avecia, Oligo Manufacturing Facility Expansion

DPS provided detailed design services to assist Avecia in increasing its oligonucleotide API manufacturing capacity with a 20,000SF expansion.

Location: Massachusetts
Sector: Oligonucleotides

About This Project

This project provides cGMP oligonucleotide manufacturing capacity up to 1.8mol, more than doubling its total capacity up to 3.0mol, making it the largest oligonucleotide manufacturing site in the world.

Project Scope

The DPS team also designed the facility to accommodate the unit 
operations of synthesis, buffer preparation, small and large chromatography, cleavage/deprotect, UF/TFE, and freeze drying. The new room layouts achieved the operations of a larger scale synthesis and chromatography suites than the existing.  The DPS team also designed an additional 7,400 sf of space to accommodate the unit operations of synthesis, buffer preparation, small and large chromatography process than the existing building.

Additionally, the design included equipment cleaning, equipment storage, flammable storage, cold storage, process utilities, USP water, and building mechanical systems.  Although the expansion is considered a separate building, to conform to building code requirements of high hazard H-3 areas, the operations were integrated and coordinated with the existing Building 155’s operations.

Back to top